Purchase this article with an account.
J. R. Gaitan, N. Z. Gregori, P. J. Rosenfeld, C. A. Puliafito, S. Dubovy, A. M. Berrocal, L. Al-Attar, H. W. Flynn, W. E. Smiddy, W. Feuer; Intravitreal Bevacizumab (Avastin®) for Macular Edema Secondary to Central Vein Occlusions. Invest. Ophthalmol. Vis. Sci. 2007;48(13):302.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate safety and efficacy of intravitreal bevacizumab (Avastin®, Genentech) for the treatment of macular edema (ME) secondary to central vein occlusions (CRVO).
A retrospective review was performed of eyes treated with intravitreal bevacizumab for ME secondary to CRVO at the Bascom Palmer Eye Institute from June 2005 to July 2006. All patients underwent routine Snellen visual acuity (VA) assessment and OCT imaging with 1 mm central retinal thickness (CRT) measurements as part of their routine clinical care. The dose of bevacizumab was 1.25 mg (0.05 ml). Retreatment was performed at monthly intervals at the discretion of the treating physician.
Forty four eyes of 44 patients were identified. Forty patients returned at 1 month, 37 at 3 months, and 19 at 6 months. Mean VA was 17 letters at baseline, 28 at 1 month, 31 at 3 months, and 26 at 6 months. Patients gained a mean of 13 ETDRS letters at 1 month (p<0.001), 13 letters at 3 months (p<0.001), and 6 letters at 6 months (p=0.016). VA increased by at least 3 lines in 63% at 1 month, 54% at 3 months, and 37% at 6 months. The mean CRT was 636 µm at baseline, 313 µm at 1 month (p<0.001, n=28), 462 µm at 3 months (p=0.001, n=32), and 464 µm at 6 months (p=0.009, n=13). VA loss of 3 Snellen lines occurred in 3% at 1 month and 5% at 3 and 6 months. Thirty four (79%) eyes received >1 injection by 6 months of follow-up.
Improvements in VA and OCT central retinal thickness measurements were observed through 6 months following intravitreal bevacizumab in patients with CRVO. These retrospective results support efforts to prospectively investigate intravitreal bevacizumab for the treatment of macular edema in retinal vein occlusions.
This PDF is available to Subscribers Only